RxDoctor Payments Data

Heather Dalton, MD

Gynecologic Oncology · Phoenix, AZNPI 1033373139

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Intuitive Surgical at 31.2% of the total. Reporting peaked in 2021 at $15,263 and has fallen 95.2% since, to $731 in 2025.

$25,610in general payments, 2019–2025

Across 149 payments — averaging $171.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$6K
  • AstraZeneca$3K
  • Eisai Inc.$2K
  • Seagen Inc.$2K
  • Tesaro, Inc.$921
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$12,93851%
  • Speaking & faculty fees$8,00031%
  • Food & beverage$4,62218%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,610 in reported general payments places this provider in the 75th percentile of 26 gynecologic oncology providers in Arizona.

See all gynecologic oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$65,019
Medicare patients
148
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib13$226,663
Estradiol17$829
Ondansetron OdtOndansetron33$460
Clobetasol Propionate17$400
Dexamethasone18$385
Lidocaine-PrilocaineLidocaine/Prilocaine16$160
Prochlorperazine Maleate21$155
Ondansetron Hcl14$112
Gabapentin12$73
Oxycodone Hcl14$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$3,154$226,66313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 26 gynecologic oncology providers in Arizona.

Other gynecologic oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →